Xilio Therapeutics, Inc.
XLO
$8.95
$0.040.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.69M | 12.65M | 13.69M | 19.07M | 8.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.69M | 12.65M | 13.69M | 19.07M | 8.08M |
| Cost of Revenue | 14.56M | 19.83M | -37.92M | 14.32M | 15.33M |
| Gross Profit | 4.13M | -7.18M | 51.60M | 4.75M | -7.25M |
| SG&A Expenses | 7.62M | 6.93M | 7.40M | 6.67M | 7.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.18M | 26.76M | 25.52M | 21.00M | 22.45M |
| Operating Income | -3.49M | -14.11M | -11.84M | -1.93M | -14.37M |
| Income Before Tax | -6.37M | -9.53M | 10.36M | -16.29M | -15.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.37M | -9.53M | 10.36M | -16.29M | -15.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.37M | -9.53M | 10.36M | -16.29M | -15.84M |
| EBIT | -3.49M | -14.11M | -11.84M | -1.93M | -14.37M |
| EBITDA | -3.16M | -13.77M | -11.51M | -1.59M | -13.99M |
| EPS Basic | -0.33 | -1.65 | 2.29 | -4.40 | -2.30 |
| Normalized Basic EPS | -0.21 | -1.03 | 1.43 | -2.75 | -1.44 |
| EPS Diluted | -0.33 | -1.65 | 2.29 | -4.40 | -2.30 |
| Normalized Diluted EPS | -0.21 | -1.03 | 1.43 | -2.75 | -1.44 |
| Average Basic Shares Outstanding | 19.40M | 5.78M | 4.53M | 3.70M | 6.89M |
| Average Diluted Shares Outstanding | 19.40M | 5.78M | 4.53M | 3.70M | 6.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |